LI LIANG: Open Payments
NPI 1053468546 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,199 in 46 payments from 12 companies in 2025. Trend: 2023 $1,475 · 2024 $1,251 · 2025 $1,199
Food & beverage: $1,199
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $282 |
| Otsuka America Pharmaceutical, Inc. | 6 | $221 |
| Alkermes, Inc. | 8 | $151 |
| Lundbeck LLC | 7 | $145 |
| Corcept Therapeutics | 1 | $104 |
| ABBVIE INC. | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $83 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| TMS NeuroHealth Centers Inc. | 1 | $18 |
Products named: REXULTI, CAPLYTA, ARISTADA, Korlym, VRAYLAR, Auvelity, FANAPT, COBENFY.
Industry payments across CA — which companies pay providers there.
